XML 75 R48.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents summary results of the Company’s reportable segments and a reconciliation of total segment operating loss to consolidated loss before income taxes (in thousands):
Year Ended December 31,
202520242023
Cell Engineering
Revenue
$132,746 $173,972 $143,531 
Costs and operating expenses:
   Cost of other revenue13,203 5,999 — 
   Research and development158,541 271,512 335,943 
   General and administrative56,532 115,028 171,210 
Cell Engineering operating loss(95,530)(218,567)(363,622)
Biosecurity
Service revenue37,409 53,071 78,975 
Product revenue— — 28,949 
Costs and operating expense:
   Cost of Biosecurity service revenue28,897 38,549 46,524 
   Cost of Biosecurity product revenue— — 7,481 
   Research and development— 771 1,599 
   General and administrative27,443 44,370 55,514 
Biosecurity operating (loss) income(18,931)(30,619)(3,194)
Total segment operating loss(114,461)(249,186)(366,816)
Reconciling items to reconcile total segment operating loss to loss before income taxes:
Stock-based compensation (1)
82,704 115,299 234,908 
Impairment expense (2)
— 53,654 121,404 
Depreciation and amortization58,990 63,020 70,507 
Restructuring charges (3)
11,398 24,172 — 
Carrying cost of excess space (net of sublease income) (4)
53,723 25,986 — 
Merger and acquisition related expenses (5)
(5,998)4,417 61,188 
Acquired in-process research and development— 19,849 9,582 
Other (income) expense, net (6)
(1,678)(8,075)28,535 
Loss before income taxes$(313,600)$(547,508)$(892,940)
(1)Includes $1.2 million, $3.0 million, and $5.0 million in related employer payroll taxes for the years ended December 31, 2025, 2024, and 2023, respectively.
(2)For 2024, includes $47.9 million related to goodwill impairment and $5.8 million related to lab equipment. For 2023, includes a $25.2 million impairment loss on lab equipment and a $96.2 million impairment loss on lease assets associated with an exited Zymergen leased facility.
(3)See Note 3, Restructuring, for composition of costs.
(4)The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
(5)Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) costs associated with the Zymergen Bankruptcy, as well as securities litigation costs, net of insurance recovery.
(6)Includes interest income, interest expense, loss on investments, losses/gains on deconsolidation of subsidiaries, changes in fair value of certain assets and liabilities, and other gains or losses.